Benoit Bouche News Today : Breaking News, Live Updates & Top Stories | Vimarsana

P95 BV ("P95"), a portfolio company of Ampersand Capital Partners and leading provider of clinical and observational services to vaccine developers, has signed an agreement to merge OnQ Research ("OnQ") into P95. The transaction, which is subject to regulatory approval and scheduled to close before year end, furthers P95's goal of becoming the leading global, vaccine-focused CRO. P95 now has unparalleled expertise conducting research in emerging geographies on the infectious diseases which could

/PRNewswire/ -- P95 BV, a global provider of epidemiology and clinical research solutions with a focus on vaccines and infectious diseases, today announced a...

Laval-based Nexelis partners with China’s JOINN for COVID-19 studies | The Laval News | Serving Laval Since 1993

Nexelis acquires the GSK vaccines clinical bioanalytical laboratory located in Marburg – Germany and enters into a 5-year strategic agreement with GSK. Laval, Quebec, and Marburg, Germany, January 20, 2021.  Nexelis,a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic […]

Share this article Share this article LAVAL, QC and MARBURG, Germany, Jan. 20, 2021 /PRNewswire/ - Nexelis, a portfolio company of Ampersand Capital Partners, and a leading provider of advanced assay development and laboratory testing services in the infectious, oncologic, and metabolic diseases fields, has signed an asset purchase agreement with GSK to acquire its GCLP-certified clinical bioanalytical laboratory located in Marburg, Germany. The Clinical Laboratory Science (CLS) team in Marburg, consisting of approximately 80 scientists and analysts, will be transferred to Nexelis. The CLS...